MedicalResearch.com Interview with:
Christian Hampp PhD
Division of Epidemiology-I, Office of Pharmacovigilance and Epidemiology
Office of Surveillance and Epidemiology
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Silver Spring, Maryland
MedicalResearch.com: What are the main findings of the study?
Dr. Hampp: We investigated the use of prescription antiobesity drugs, including duration of use, in the United States from 2002 through 2011. We found that in 2011, approximately 2.74 million patients used antiobesity drugs, predominantly phentermine (2.43 million patients), while the use of prescription orlistat and sibutramine was relatively uncommon. Eighty-five percent of antiobesity drug users were female, 62% were aged 17-44 years, and 4.5% had a body mass index of ≤24.9 kg/m2. Duration of use was generally short and most patients only had one episode of antiobesity drug use during the observation period. The longest episode of use was ≤30 days in 47- 58% of patients. Approximately one quarter of patients used antiobesity drugs for longer than 90 days. Only 1.3- 4.2% of antiobesity drug users used them for >1 year.
(more…)